ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is PTC Therapeutics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 32.94% of over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 0.34 times
2
The company has declared Negative results for the last 3 consecutive quarters
- NET SALES(HY) At USD 633.07 MM has Grown at -53.28%
- NET PROFIT(HY) At USD 81.61 MM has Grown at -89.81%
- INTEREST(HY) At USD 97.51 MM has Grown at 51.3%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 60.46%, its profits have risen by 413% ; the PEG ratio of the company is 0
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is PTC Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
PTC Therapeutics, Inc.
49.41%
2.24
41.62%
S&P 500
20.6%
1.55
13.08%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
35.37%
EBIT Growth (5y)
32.94%
EBIT to Interest (avg)
-2.26
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
9.29
Sales to Capital Employed (avg)
4.72
Tax Ratio
8.68%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
8
Industry P/E
Price to Book Value
-26.66
EV to EBIT
4.47
EV to EBITDA
4.28
EV to Capital Employed
-2.07
EV to Sales
2.21
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend17What is working for the Company
RAW MATERIAL COST(Y)
Fallen by 0.18% (YoY
CASH AND EQV(HY)
Highest at USD 4,121.55 MM
NET SALES(Q)
Highest at USD 360.52 MM
OPERATING PROFIT(Q)
Highest at USD 164.85 MM
OPERATING PROFIT MARGIN(Q)
Highest at 45.73 %
PRE-TAX PROFIT(Q)
Highest at USD 97.55 MM
NET PROFIT(Q)
Highest at USD 83.5 MM
EPS(Q)
Highest at USD 0.92
-24What is not working for the Company
NET SALES(HY)
At USD 633.07 MM has Grown at -53.28%
NET PROFIT(HY)
At USD 81.61 MM has Grown at -89.81%
INTEREST(HY)
At USD 97.51 MM has Grown at 51.3%
DEBT-EQUITY RATIO
(HY)
Highest at 926.82 %
DEBTORS TURNOVER RATIO(HY)
Lowest at 4.64 times
Here's what is working for PTC Therapeutics, Inc.
Net Sales
At USD 360.52 MM has Grown at 74.35%
over average net sales of the previous four periods of USD 206.78 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 97.55 MM has Grown at 259.62%
over average net sales of the previous four periods of USD -61.11 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 83.5 MM has Grown at 270.83%
over average net sales of the previous four periods of USD -48.88 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 360.52 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 164.85 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 45.73 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 97.55 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 83.5 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.92
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 4,121.55 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by 0.18% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 15.87 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for PTC Therapeutics, Inc.
Interest
At USD 97.51 MM has Grown at 51.3%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at 926.82 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Debtors Turnover Ratio
Lowest at 4.64 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
